Skip to main content

Table 1 p values for MMRM analysis modeling the association of anti-CarbV/anti-MCV antibodies with SDAI response

From: Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN

MMRM variable

Anti-CarbV antibody isotypes

Anti-MCV antibody isotypes

IgA

IgG

IgM

IgA

IgG

IgM

Time

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

Treatment

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

Baseline antibody (only in MMRM with linear association)

NA

0.033

0.981

NA

NA

NA

Baseline antibody NCS (in MMRM with nonlinear association)

0.002

NA

NA

0.323

0.503

0.036

Baseline SDAI

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

Baseline ACPA

0.702

0.759

0.957

0.912

0.863

0.980

Baseline RF

0.120

0.123

0.965

0.109

0.155

0.132

Erosions

0.301

0.447

0.375

0.317

0.302

0.318

Age

0.410

0.378

0.430

0.365

0.372

0.168

Sex

0.826

0.753

0.870

0.839

0.749

0.656

BMI

0.763

0.881

0.716

0.830

0.860

0.873

Geographic region

0.020

0.045

0.071

0.056

0.053

0.057

Time-by-treatment interaction

0.633

0.633

0.633

0.633

0.633

0.633

Baseline antibody-by-treatment interaction

NA

NA

< 0.001

NA

NA

NA

  1. Different nested MMRM were compared employing a chi-squared LRT to select between linear (baseline antibody in the MMRM) or nonlinear associations defined with a natural cubic spline (baseline antibody using an NCS in the MMRM) and to test baseline antibody-by-treatment interactions. p values < 0.05 were considered statistically significant. The reported p values obtained from the multivariable model are for the association between the corresponding factor and overall SDAI response, measured as CFB, while controlling for the influence of all other factors included in the model: SDAI; time (visit: weeks 4, 12, 16, 20, 24, 32, 40, and 52); treatment (MTX, baricitinib 4 mg, baricitinib 4 mg + MTX); baseline antibody, in MMRM with linear association or baseline antibody using NCS, in MMRM with NCS with 3 degrees of freedom (nonlinear association); ACPA (yes/no); RF (yes/no); erosions: presence of erosions at baseline (yes/no); geographic region (Central and South America and Mexico; Europe; Japan; Rest of the World, USA and Canada); BMI; baseline antibody-by-treatment interaction, only in MMRM with (significant) baseline antibody-by-treatment interaction
  2. ACPA anti-citrullinated protein antibody, BMI body mass index, CarbV carbamylated vimentin, CFB change from baseline, Ig immunoglobulin, LRT likelihood-ratio test, MCV mutated citrullinated vimentin, MMRM mixed model for repeated measures, MTX methotrexate, NA factor not estimated in the MMRM used for that specific antibody, NCS natural cubic spline, RF rheumatoid factor, SDAI Simplified Disease Activity Index
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us